A Case Study of Personalized Medicine

See allHide authors and affiliations

Science  04 Apr 2008:
Vol. 320, Issue 5872, pp. 53-54
DOI: 10.1126/science.1156604

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed.  Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Enter the characters shown in the image.

Vertical Tabs

  • Assessing Drug Metabolism

    I read with interest the short Policy Forum article on personalized medicine ("A case study of personalized medicine," by S. H. Katsanis et al., 4 April 2008, p. 53). I was surprised that while the terms “genotype” and “gene” were mentioned nearly 20 times in the short article, the word “phenotype” never appeared.

    It is increasingly clear in the area of drug metabolism, it is increasingly clear that genotype d...

    Show More
    Competing Interests: None declared.
  • Promises, Promises

    S. H. Katsanis, G. Javitt, and K. Hudson begin their otherwise excellent Policy Forum ("A case study of personalized medicine," 4 April 2008, p. 53) with the sentence, "Personalized medicine through pharmacogenetics promises to revolutionize health care…" Use of the word "promises" is an example of genohype (1). In a PubMed search (April 14, 2008) I found the words "promise" or "promises" in 104 of the 1,735 (6 %) arti...

    Show More
    Competing Interests: None declared.
  • Global Direct-to-Consumer Marketing Strategies Call for Global Oversight

    We fully agree with the authors' call for enhanced enforcement by Federal Trade Commission (FTC) in oversight of misleading claims made by direct-to-consumer (DTC) genetics testing, as well as for the development of a mandatory registry of such providers (Policy Forum, "A case study of personalized medicine," by S. H. Katsanis et al., 4 April 2008, p. 53). The problem has been recognized in Europe as well. The need for...

    Show More
    Competing Interests: None declared.